上海
埃萬妥單抗聯合治療方案為不同EGFR突變晚期NSCLC人群提供精準治療選擇。
*以下內容僅供醫療衛生專業人士瀏覽。
參考文獻：
[1] 中華醫學會腫瘤學分會. 中華醫學會肺癌臨床診療指南（2025版）[J]. 中華腫瘤雜志, 2025, 47(9): 769-810.
[2] Boustany Y, et al. Prevalence and Patterns of EGFR Mutations in Non-small Cell Lung Cancer in the Middle East and North Africa. Cancer Control. 2022;29: 1-9.
[3] Zhou C, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051.
[4] Zhou C. et al. Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPILLON subgroup analysis. 2023 ESMO Asia.513MO.
[5]Cho BC, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024 Oct 24;391(16):1486-1498.
[6]Yang JC, et al. MARIPOSA Investigators. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2025 Sep 7.
[7]Lu S, et al. Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment Among Asian Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): MARIPOSA Subgroup Analysis. 2023 ESMO Aisa. LBA10.
審批編碼：CP-558517
批準分發日期：12/16/2025
有效期：12/16/2026
*“醫學界”力求所發表內容專業、可靠，但不對內容的準確性做出承諾；請相關各方在采用或以此作為決策依據時另行核查。
特別聲明：以上內容(如有圖片或視頻亦包括在內)為自媒體平臺“網易號”用戶上傳并發布，本平臺僅提供信息存儲服務。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
